$3.35
1.21% yesterday
Nasdaq, Dec 24, 10:22 pm CET
ISIN
US00847G7051
Symbol
AGEN

Agenus Inc. Stock price

$3.35
-0.94 21.91% 1M
-1.65 33.00% 6M
+0.61 22.26% YTD
+0.60 21.82% 1Y
-44.73 93.03% 3Y
-63.18 94.96% 5Y
-90.46 96.43% 10Y
-590.14 99.44% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.04 1.21%
ISIN
US00847G7051
Symbol
AGEN
Industry

Key metrics

Basic
Market capitalization
$113.9m
Enterprise Value
$439.9m
Net debt
$326.0m
Cash
$3.5m
Shares outstanding
32.8m
Valuation (TTM | estimate)
P/E
negative | 3.5
P/S
1.1 | 0.7
EV/Sales
4.1 | 2.5
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-144.2%
Return on Equity
69.7%
ROCE
118.2%
ROIC
-
Debt/Equity
-1.2
Financials (TTM | estimate)
Revenue
$106.8m | $172.9m
EBITDA
$-50.3m | $-148.1m
EBIT
$-62.9m | $48.6m
Net Income
$-35.4m | $31.7m
Free Cash Flow
$-89.3m
Growth (TTM | estimate)
Revenue
-33.4% | 67.2%
EBITDA
41.2% | -33.3%
EBIT
37.6% | 139.0%
Net Income
84.5% | 113.9%
Free Cash Flow
47.7%
Margin (TTM | estimate)
Gross
98.9%
EBITDA
-47.1% | -85.6%
EBIT
-58.9%
Net
-33.1% | 18.3%
Free Cash Flow
-83.6%
More
EPS
$-1.1
FCF per Share
$-2.7
Short interest
5.3%
Employees
316
Rev per Employee
$330.0k
Show more

Is Agenus Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Agenus Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Agenus Inc. forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Agenus Inc. forecast:

Buy
78%
Hold
22%

Financial data from Agenus Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
107 107
33% 33%
100%
- Direct Costs 1.14 1.14
81% 81%
1%
106 106
34% 34%
99%
- Selling and Administrative Expenses 63 63
13% 13%
59%
- Research and Development Expense 106 106
44% 44%
99%
-50 -50
41% 41%
-47%
- Depreciation and Amortization 13 13
17% 17%
12%
EBIT (Operating Income) EBIT -63 -63
38% 38%
-59%
Net Profit -35 -35
84% 84%
-33%

In millions USD.

Don't miss a Thing! We will send you all news about Agenus Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Agenus Inc. Stock News

Neutral
Business Wire
2 days ago
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the publication of clinical results from the ovarian cancer cohort of its Phase 1b C-800-01 trial evaluating botensilimab plus balstilimab (BOT+BAL) in The Journal for ImmunoTherapy of Cancer (JITC). The peer-reviewed manuscript titled, “Botensilimab (Fc-enhanced...
Neutral
Seeking Alpha
22 days ago
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript
Neutral
Business Wire
about one month ago
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BATTMAN--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its End-of-Year 2025 Stakeholder Webcast on Wednesday, December 3, 2025 at 4:00 p.m. ET. The session will feature leading experts in gastrointestinal oncology and patient advocates discussing progress with the BOT/BAL program, emerging clinical i...
More Agenus Inc. News

Company Profile

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.

Head office United States
CEO Garo Armen
Employees 316
Founded 1994
Website agenusbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today